摘要
目的:探讨晚期糖基化终产物(advanced glycation end products,AGEs)对肝癌细胞耐药性的影响及其机制。方法:体外培养人肝癌细胞HepG2,以终浓度分别为100、200、400μg.ml-1的AGEs联合2 000 nmol.L-1盐酸阿霉素(adramycin,ADM)处理细胞24 h,并设空白对照和ADM组进行比较。应用倒置显微镜观察不同浓度AGEs联合ADM孵育下HepG2形态学变化,流式细胞术(flow cytometry,FCM)检测细胞周期的改变,应用细胞计数试剂盒(cell counting kit-8,CCK-8)检测细胞株活性,蛋白质免疫印迹法(Western blotting)测定不同浓度AGEs作用下,HepG2细胞多药耐药基因(multidrug resistance-1,MDR1)蛋白表达情况。结果:在2 000 nmol.L-1ADM作用下,HepG2细胞生长停滞或死亡,而AGEs能促进细胞生长,抑制其死亡。细胞周期和细胞活性实验表明,与ADM组相比,随着AGEs浓度增加,G1期细胞百分率显著下降,S期及G2期细胞增加,细胞活性有上升趋势。Western blotting检测表明AGEs能增加MDR1的蛋白表达。结论:AGEs能通过促进MDR1基因的表达,降低肿瘤细胞对化疗药物的敏感性。
Objective： To investigated the effects of advanced glycation end products （AGEs） on the multidrug resistance of HepG2 cells and its mechanism. Methods： Human hepatocellular carcinoma HepG2 ceils were cultured and exposed to AGEs at the concentration of 100,200 and 400μg· ml-1 combined with 2 000 nmol ·L-1adramycin（ADM） for 24 hours in vitro, normal control group and ADM group were established for comparison. Inverted microscope was used to observe the change of cell morphous. The flow cytometry （FCM） was used to investigate cell cycle and cell counting kit-8 （CCK-8） assay was used to assess the cell activity. Western blotting
出处
《东南大学学报（医学版）》
CAS
2013年第4期399-403,共5页
Journal of Southeast University(Medical Science Edition)
基金
国家自然科学基金资助项目(81170254
30973475)
关键词
晚期糖基化终产物
人肝癌HEPG2细胞
多药耐药
advanced glycation end products
human hepatocellular carcinoma HepG2 cells
multidrug resistance
